Anti-TNF Treatment in Crohn's Disease: Toward Tailored Therapy?

被引：7
|
作者：
D'Haens, Geert [1 ,2 ]
机构：
[1] Imelda GI Clin Res Ctr, Bonheiden, Belgium
[2] Univ Leuven, Louvain, Belgium
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷 / 05期
关键词：
SCHEDULED MAINTENANCE TREATMENT; RANDOMIZED-TRIAL; INFLIXIMAB; ADALIMUMAB; ANTIBODIES;
D O I：
10.1038/ajg.2010.15
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
引用
收藏
页码：1140 / 1141
页数：2
相关论文
共 50 条
  • [41] Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy
    Roussomoustakaki, M
    Dimoulios, P
    Chatzicostas, C
    Kritikos, HD
    Romanos, J
    Panayiotides, JG
    Kouroumalis, EA
    JOURNAL OF GASTROENTEROLOGY, 2003, 38 (10) : 1000 - 1004
  • [42] Effect of anti-TNFα therapy with daily physical activity in patients with Crohn's disease
    Lucca, F. A.
    Malaguti, C.
    Cabalzar, A. L.
    Chebli, L. A.
    Ribeiro, T. C. R.
    Gaburri, P. D.
    Chebli, J. M. F.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S344 - S344
  • [43] Long-term anti-TNFα therapy for perianal fistulising Crohn's disease
    Kiel, N.
    Ooi, S. Y.
    Kienzle, N.
    Radford-Smith, G. L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 103 - 103
  • [44] Association of serum VEGF with clinical response to anti-TNFα therapy for Crohn's disease
    Eder, Piotr
    Korybalska, Katarzyna
    Lykowska-Szuber, Liliana
    Krela-Kazmierczak, Iwona
    Stawczyk-Eder, Kamila
    Klimczak, Katarzyna
    Szymczak, Aleksandra
    Linke, Krzysztof
    Witowski, Janusz
    CYTOKINE, 2015, 76 (02) : 288 - 293
  • [45] A Case of Hidradenitis Suppurativa Refractory to Anti-TNFα Therapy in a Patient With Crohn's Disease
    Koilakou, Stavroula
    Karapiperis, Dimitrios
    Tzathas, Charalampos
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (01): : 231 - 232
  • [46] MUCOSAL HEALING IN ANTI-TNF REFRACTORY/INTOLERANT CROHN'S DISEASE WITH THALIDOMIDE THERAPY
    Scribano, M. L.
    Marrollo, M.
    Cantoro, L.
    Cosintino, R.
    Prantera, C.
    Kohn, A.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S221 - S222
  • [47] Infliximab as Second Anti-TNF Agent in Crohn's Disease: Durability and Tolerance of Therapy
    Gonzaga, Jason E.
    Zadvornova, Yelena
    Stein, Daniel J.
    Perera, Lilani P.
    Naik, Amar S.
    Venu, Nanda
    GASTROENTEROLOGY, 2012, 142 (05) : S249 - S249
  • [48] Safety considerations when using anti-TNFα therapy to treat Crohn's disease
    Pagnini, Cristiano
    Arseneau, Kristen O.
    Cominelli, Fabio
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 31 - 44
  • [49] Increased Risk of Surgery After Attenuation of Anti-TNFα Therapy for Crohn's Disease
    Bosworth, Brian P.
    Lebwohl, Benjamin
    Taunk, Raja
    Green, Nicole
    Lakehomer, Harrison
    Iroku, Ugonna
    Swaminath, Arun
    Milsom, Jeffrey W.
    Michelassi, Fabrizio
    Scherl, Ellen J.
    GASTROENTEROLOGY, 2010, 138 (05) : S856 - S856
  • [50] The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease
    Mascheretti, S
    Schreiber, S
    PHARMACOGENOMICS, 2004, 5 (05) : 479 - 486
12345